Jump to content

malagabears

Members
  • Content Count

    445
  • Joined

  • Last visited

Community Reputation

195 Veteran

1 Follower

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

  1. I like it for depth. https://twitter.com/MikeGarafolo/status/1302548998218276864?s=20
  2. NHL to boycott possibly 1 playoff game. https://twitter.com/DarrenDreger/status/1299040711678062593?s=20
  3. NBA & MLB have started boycotts. The NBA Lakers & Clippers want to punt the season. The Brewers have boycotted 1 game but who knows what can & will happen. Do you think the NFLPA will follow suit?
  4. OK, I am back after a small hiatus. @soulman get the coffee brewing. 😝
  5. Webmaster, if I want to leave the forum and delete my account how do I go about it?
  6. https://twitter.com/TomPelissero/status/1256670150536892416?s=20
  7. @TLO @mission27 Spain made great strides today, only 288 fatalities & 1.7K new infections but 3K recovered!!!
  8. @mission27 Spain finally has numbers indicating the curve may be on it's way down. 3105 cured, 2796 new infections, & 367 fatalities yesterday.
  9. Promising vaccine candidate: https://www.mymcmedia.org/gaithersburg-lab-one-step-closer-to-potential-covid-19-vaccine/ A local bio-technology company has found a coronavirus vaccine candidate, and the first in-human trial is expected to begin in May. Novavax, which is located in Gaithersburg, develops next-generation vaccines for serious infectious diseases. Officials say they will be using NVX-CoV2373, which is described as a stable, prefusion protein made using Novavax’s proprietary nanoparticle technology. “Our scientists identified an ideal vaccine candidate selected from a number of constructs and, in partnership with Dr. Matthew Frieman, demonstrated that NVX-CoV2373 produced high levels of neutralizing antibodies against SARS-CoV-2 in animal studies,” said Gregory Glenn, M.D., President of Research and Development at Novavax. “In addition, we have worked closely with our colleagues at Emergent BioSolutions to transfer our production technology that allows the manufacture of GMP vaccine for clinical trials. With preliminary CEPI funding, these heroic efforts, combined with the candidate’s excellent early results, put us in position to have preliminary human data in July.” According to a press release, the clinical development plan combines a two phase approach to allow rapid advancement during the current coronavirus health crisis. The phase one clinical trial is a placebo-controlled study of 130 healthy adults and includes assessment of dosage amount and number of vaccinations. The trial is expected to begin in mid-May, and preliminary results are expected in July. “We validated that NVX-CoV2373 generates high titer neutralizing antibodies against live SARS-CoV-2 virus,” said Matthew Frieman, Ph.D., Associate Professor at the University of Maryland School of Medicine. “This is strong evidence that the vaccine created by Novavax has the potential to be highly immunogenic in humans which could lead to protection from COVID-19 and helping to control the spread of this disease.”
  10. @mission27 Today the numbers are steady, 435 fatalities & 4211 new infections. The latest extension to the stay at home will end on 9 May. At that point we should be in tier I. I think by next week the number of recovered will surpass the infections on a daily basis.
  11. @mission27 Spain is still in Tier II finding it very difficult to get over the hump down into the 2-3 range. Today better numbers but cannot see us getting into tier I for another 10-14 days. Our stay at home social distancing will be extended until 9 May it looks like.
  12. @TLO, @mission27, Spain is looking better by the day. Infections seem to be leveling off. 3577 infections yesterday & 517 deaths. What is really polarizing is that of our 17,489 recorded deaths 9900 are from nursing homes alone.
×
×
  • Create New...